Genocea Biosciences, Inc. (NASDAQ:GNCA) enjoyed a 2.91% run-up in share price since hitting record low of $1.03. The stock managed -5.36% fall and now stands at $1.06 as of 12/06/2017. At recent session, the prices were hovering between $1.06 and $1.12. This company shares are 591.51% off its target price of $7.33 and the current market capitalization stands at $28.94M. The recent change has given its price a -18.94% deficit over SMA 50 and -85.46% deficit over its 52-week high. The stock witnessed -16.54% declines, -80.26% declines and -82.71% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found GNCA’s volatility during a week at 7.23% and during a month it has been found around 7.95%.Genocea Biosciences, Inc. (GNCA) Top Holders
Institutional investors currently hold around $11 million or 40.3% in GNCA stock. Look at its top three institutional owners. Polaris Venture Management Co. V, L.L.C. owns $2.21 million in Genocea Biosciences, Inc., which represents roughly 7.62% of the company’s market cap and approximately 20.05% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 1,459,997 shares of the stock are valued at $1.64 million. The third largest holder is Vanguard Group Inc, which currently holds $1.06 million worth of this stock and that ownership represents nearly 3.67% of its market capitalization.Genocea Biosciences, Inc. 13F Filings
At the end of 09/30/2017 reporting period, 33 institutional holders increased their position in Genocea Biosciences, Inc. (NASDAQ:GNCA) by some 836,142 shares, 24 decreased positions by 7,845,220 and 15 held positions by 1,291,584. That puts total institutional holdings at 9,972,946 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 599,722 shares while 10 institutional investors sold out their entire positions totaling 3,905,783 shares.
Multiple company employees have indulged in significant insider trading. Genocea Biosciences, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO Poole Jonathan has sold 45,000 shares of Genocea Biosciences, Inc. (GNCA) in trading session dated Jul. 24, 2017. These shares are worth $270,000 and were traded at $6 each. The SEC filing shows that Poole Jonathan performed a sale of 6,213 shares. The CFO disposed these shares by way of transaction on May. 08, 2017. The company’s shares were given away at $6.51 per share worth to an income of some $40,447 on account of Poole Jonathan.
Chief Business Officer, Hoffman Eric S, purchased 7,000 common shares of Genocea Biosciences, Inc. (GNCA) in the open market. In a transaction dated Nov. 08, 2016, the shares were bought at an average price of $3.49, giving away a sum of $24,430. After this purchase, 11,790 common shares of GNCA are directly owned by the insider, with total stake valued at $12,497.
In the transaction dated Nov. 07, 2016, the great number of shares acquired came courtesy the CFO; Poole Jonathan added a total of 7,000 shares at an average price of $3.34, amounting to approximately $23,380. The insider now directly owns 17,213 shares worth $18,246.Genocea Biosciences, Inc. (GNCA) Analyst Guide
Several analysts have released their opinion on Genocea Biosciences, Inc. (NASDAQ:GNCA), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation.